Company intelligence / Profile preview

Grandway SaviTrust Life Sciences

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Grandway SaviTrust Life Sciences is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative small molecule therapeutics for metabolic diseases. The company's primary focus is on developing oral, non-peptide agonists for the glucagon-like peptide 1 receptor (GLP-1R) and related metabolic targets. Their lead candidate, GS-002, is an oral small molecule GLP-1 receptor agonist currently in clinical development for the treatment of type 2 diabetes and obesity. By leveraging small molecule chemistry, the company aims to provide more convenient and accessible alternatives to injectable peptide-based metabolic therapies.

Therapeutic areas: EndocrinologyGastroenterologyMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Grandway SaviTrust Life Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Grandway SaviTrust Life Sciences.

Explore the full profile